Evaluation of safety and immunogenicity of recombinant influenza hemagglutinin (H5/Indonesia/05/2005) formulated with and without a stable oil-in-water emulsion containing glucopyranosyl-lipid A (SE+GLA) adjuvant

Vaccine

Volumn 31, Issue 48, 2013, Pages 5760-5765

  Treanor, John J ^a   Essink, Brandon ^b   Hull, Steven ^c   Reed, Steven ^d   Izikson, Ruvim ^e   Patriarca, Peter ^f   Goldenthal, Karen L ^g   Kohberger, Robert ^h   Dunkle, Lisa M ^e  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b Meridian Clinical Research   (United States)

^c Vince and Associates Clinical Research   (United States)

^d Immune Design Corp   (United States)

^e Protein Sciences Corp   (United States)

^f BIOLOGICS CONSULTING GROUP INC   (United States)

^g Independent Consultant   (United States)

^h Independent Consultant   (United States)

Author keywords

Adjuvants; H5N1; Pandemic influenza; Vaccines

Indexed keywords

BACULOVIRUS VECTOR; GLUCOPYRANOSYL LIPID A; INFLUENZA VACCINE; LIPID EMULSION; NEUTRALIZING ANTIBODY; PLACEBO; RECOMBINANT DNA; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ARTHRALGIA; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CHILL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG SAFETY; EVALUATION; FATIGUE; FEVER; FOLLOW UP; HEADACHE; HEMAGGLUTINATION INHIBITION; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSECT CELL; LIMIT OF DETECTION; MYALGIA; NANOEMULSION; NAUSEA; NONHUMAN; NORMAL HUMAN; PANDEMIC; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ADJUVANTS; H5N1; PANDEMIC INFLUENZA; VACCINES;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, VIRAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EMULSIONS; FEMALE; HEALTHY VOLUNTEERS; HEMAGGLUTINATION INHIBITION TESTS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; LIPID A; MALE; MIDDLE AGED; PLACEBOS; RECOMBINANT PROTEINS; VACCINES, SYNTHETIC; YOUNG ADULT;

EID: 84886950936     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.08.064     Document Type: Article

References (28)

1. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 2004, 350:1179-1188.
2. Timothy M.U. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis 2009, 49:279-290.
3. Herfst S., Schrauwen E.J.A., Linster M., Chutinimitkul S., de Wit E., Munster V.J., et al. Airborne transmission of influenza A/H5N1 virus between ferrets. Science 2012, 336:1534-1541.
4. Imai M., Watanabe T., Hatta M., Das S.C., Ozawa M., Shinya K., et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 2012, 486:420-428.
5. Russell C.A., Fonville J.M., Brown A.E.X., Burke D.F., Smith D.L., James S.L., et al. The potential for respiratory droplet-transmissable A/H5N1 influenza virus to evolve in a mammalian host. Science 2012, 336:1541-1547.
6. Cox M.M.J., Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol 2011, 107:S31-S41.
7. Wang K., Holtz K.M., Anderson K., Chubet R., Mahmoud W., Cox M.M.J. Expression and purification of an influenza hemagglutinin-one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006, 24:2176-2185.
8. Treanor J.J., Schiff G.M., Hayden F.G., Brady R.C., Hay C.M., Meyer A.L., et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007, 297:1577-1582.
9. Treanor J.J., El Sahly H.M., King J.C., Graham I., Izikson R., Kohberger R., et al. Protective efficacy of a trivalent, recombinant hemagglutinin protein vaccine (FluBlok) against influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011, 39:7733-7739.
10. Treanor J.J., Schiff G.M., Couch R.B., Cate T.R., Brady R.C., Hay C.M., et al. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006, 193:1223-1228.
11. Baxter R., Patriarca P.A., Ensor K., Izikson R., Goldenthal K.L., Cox M.M. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011, 29:2272-2278.
12. Keitel W.A., Treanor J., El Sahly H.M., Gilbert A., Maeyer A.L., Patricarca P.A., et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIVs) among persons ≥65 years old. Vaccine 2009, 28:379-385.
13. Keitel W.A., Campbell J.D., Treanor J.J., Walter E., Patel S.M., He F., et al. Safety and immunogenicity of an inactivated influenza A/H5N1 vaccine given with or without aluminum hydroxide to healthy adults: results of a phase I/II randomized clinical trial. J Infect Dis 2008, 198:1309-1319.
14. Treanor J.J., Campbell J.D., Zangwill K.M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
15. Treanor J.J., Wilkinson B.E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans vaccine. Vaccine 2001, 19:1732-1737.
16. Bernstein D.I., Edwards K.M., Dekker C.L., Belshe R., Talbot H.K.B., Graham I.L., et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008, 197:667-675.
17. Caillet C., Piras F., Bernard M.-C., de Montfort A., Boudet F., Vogel F.R., et al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 2010, 20:3076-3079.
18. Moris P., Most R., Leroux-Roels I., Clement F., Dramé M., Hanon E., et al. H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011, 31:443-454.
19. Coler R.N., Bertholet S., Moutaftsi M., Guderian J.A., Windish H.P., Baldwin S.L., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 2011, 6:e16333. 10.1371/journal.pone.0016333.
20. ® adjuvanted with a synthetic TLR4 agonist formulated in an emulsion. Vaccine 2009, 27:5956-5963.
21. S. Reed, Personal communication, 2011.
22. Noah D.L., Hill H., Hines D., White E.L., Wolff M.C., et al. Qualification of the hemagglutination inhibition assay in support of pandemic influenza vaccine licensure. Clin Vaccine Immunol 2009, 16:558-566.
23. CBER/FDA Guidance for Industry: Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccine. s.l.: DHHS/FDA/CBER 2007.
24. Beigel J.H., Voell J., Huang C-y, Burbelo P.D., Lane H.C. Safety and Immunogenicity of multiple and higher doses of an inactivated influenza A/H5N1 vaccine. J Infect Dis 2009, 200:501-509.
25. Lasko B., Reich D., Madan A., Roman F., Li P., Vaughn D. Rapid immunization against H5N1: a randomized trial evaluating homologous and cross-reactive immune responses to AS03A-adjuvanted vaccination in adults. J Infect Dis 2011, 204:574-581.
26. Lopez P., Caicedo Y., Sierra A., Tilman S., Banzhoff A., Clemens R. Combined, concurrent and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized controlled trial of immunogenicity and safety in healthy adults. J Infect Dis 2011, 203:1719-1728.
27. Goji N.A., Nolan C., Hill H., Wolff M., Rowe T., Treanor J.J. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/04 (H5N1) vaccine after priming with an antigenic variant. J Infect Dis 2008, 198:635-641.
28. Ehrlich H.J., Müller M., Fritsch S., Zeitlinger M., Berezuk G., Löw-Baselli A., et al. A cell-culture (Vero)-derived H5N1 whole-virus vaccine induces cross-reactive memory responses. J Infect Dis 2009, 200:1113-1118.